LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Matz, M.; Coleman, M.; Carreira, H.; Salmerã³n, D.; Chirlaque, M.; Allemani, C.; Bouzbid, S.; Hamdi-chérif, M.; Zaidi, Z.; Bah, E.; Swaminathan, R.; Nortje, S.; El Mistiri, M.; Bayo, S.; Malle, B.; Manraj, S.; Sewpaul-sungkur, R.; Fabowale, A.; Ogunbiyi, O.; Bradshaw, D.; Somdyala, N.; Stefan, D.; Abdel-rahman, M.; Jaidane, L.; Mokni, M.; Kumcher, I.; Moreno, F.; González, M.; Laura, E.; Espinola, S. ... view all 501 authors View less authors (2017)
Publisher: Academic Press Inc.
Languages: English
Types: Article
Subjects: epidemiology; histology; morphology; ovarian cancer; stage; survival; Adolescent; Adult; Aged; Aged, 80 and over; Female; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Oncology; Obstetrics and Gynecology, Settore MED/42 - Igiene Generale E Applicata
Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15-99years) diagnosed with ovarian cancer during 1995-2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). Survival from type I epithelial ovarian tumours for women diagnosed during 2005-09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20-45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • 1. Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al. Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 populationbased registries in 67 countries (CONCORD-2). Lancet. 2015;385(9972):977-1010.
    • 2. Maringe C, Walters S, Butler J, Coleman MP, Hacker N, Hanna L, et al. Stage at diagnosis and ovarian cancer survival: evidence from the International Cancer Benchmarking Partnership. Gynecologic Oncology. 2012;127(1):75-82.
    • 3. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study. Lancet Oncol. 2014;15(1):23-34.
    • 4. Kurman RJ, Shih Ie M. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34(3):433-43.
    • 5. Kurman RJ, Shih Ie M. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol. 2011;42(7):918-31.
    • 6. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol. 2008;61(2):152-63.
    • 7. Banerjee S, Kaye SB. New strategies in the treatment of ovarian cancer: current clinical perspectives and future potential. Clin Cancer Res. 2013;19(5):961-8.
    • 8. Fritz AG, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin DM, et al., editors. International Classification of Diseases for Oncology (ICD-O). 3rd ed. Geneva: World Health Organization; 2000.
    • 9. Trent Cancer Registry: National Cancer Intelligence Network. Overview of Ovarian Cancer in England: Incidence, Mortality and Survival. London: National Cancer Intelligence Network, 2012.
    • 10. Pohar Perme M, Henderson R, Stare J. An approach to estimation in relative survival regression. Biostatistics. 2009;10:136-46.
    • 11. Clerc-Urmès I, Grzebyk M, Hédelin G. Net survival estimation with stns. Stata Journal. 2014;14:87-102.
    • 12. StataCorp. STATA statistical software. 14 ed. College Station TX: Stata Corporation; 2015.
    • 13. Corazziari I, Quinn MJ, Capocaccia R. Standard cancer patient population for age standardising survival ratios. European Journal of Cancer. 2004;40:2307-16.
    • 14. Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. WHO Classification of Tumours of Female Reproductive Organs. 4th ed. Geneva: WHO; 2014.
    • 15. Kurman RJ, Shih Ie M. The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded. Am J Pathol. 2016;186(4):733-47.
    • 16. Oberaigner W, Minicozzi P, Bielska-Lasota M, Allemani C, de Angelis R, Mangone L, et al. Survival for ovarian cancer in Europe: the across-country variation did not shrink in the past decade. Acta Oncol. 2012;51(4):441-53.
  • No related research data.
  • No similar publications.